|Articles|July 24, 2019
Versiti Acquires Cenetron Central Laboratories and Salus IRB
Advertisement
Versiti has announced the acquisition of Texas-based Cenetron Central Laboratories, and its subsidiary, Salus IRB. The acquisition will not impact Cenetron’s 40 employees, and the laboratory will maintain its name and current location in Austin.
For more details, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
2
Phase IV Trial Shows Strong Immune Response from Moderna’s Updated Spikevax Against LP.8.1 Variant of COVID-19
3
Enhancing Clinical Trial Data Accuracy Through the IQVIA and Veeva Partnership
4
Everything to Know About FDA’s Push Towards Radical Transparency in 2025
5